US biotech company Senesco Technologies is running a Phase I/II study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic translation initiation factor 5A (eIF5A) to modulate critical pathways involved in cancer and inflammatory diseases is being investigated. At the end of 2013 it agreed to merge with Fabrus.